3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Graft vs Host Disease
1
Cholangiocarcinoma
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cyclophosphamide
18
fludarabine phosphate
12
pembrolizumab
11
Nivolumab
11
Brentuximab Vedotin
11
Mycophenolic Acid
10
Doxorubicin
10
fludarabine
9
Dacarbazine
9
Whole-Body Irradiation
8
Etoposide
8
Vinblastine
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Filgrastim
7
Cyclosporine
7
Granulocyte Colony-Stimulating Factor
6
Sirolimus
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Gemcitabine
5
Busulfan
5
Tacrolimus
4
pegfilgrastim
3
Vinorelbine
3
Stem Cell Transplantation
3
Rituximab
3
Radiation
3
Prednisone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
axatilimab
×
90 days
×
Clear all
NCT05723055
2026-05-08
NAHL
University of Utah
Phase 2
Active not recruiting
9 enrolled